<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS139954</article-id>
<article-id pub-id-type="doi">10.1101/2021.11.17.468942</article-id>
<article-id pub-id-type="archive">PPR421703</article-id>
<article-version article-version-type="publisher-id">2</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>SARS-CoV-2 variants of concern remain dependent on IFITM2 for efficient replication in human lung cells</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Nchioua</surname>
<given-names>Rayhane</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schundner</surname>
<given-names>Annika</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kmiec</surname>
<given-names>Dorota</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Prelli-Bozzo</surname>
<given-names>Caterina</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zech</surname>
<given-names>Fabian</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Koepke</surname>
<given-names>Lennart</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Graf</surname>
<given-names>Alexander</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Krebs</surname>
<given-names>Stefan</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Blum</surname>
<given-names>Helmut</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Frick</surname>
<given-names>Manfred</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sparrer</surname>
<given-names>Konstantin M. J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kirchhoff</surname>
<given-names>Frank</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">#</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany</aff>
<aff id="A2">
<label>2</label>Institute of General Physiology, Ulm University Medical Center, 89081 Ulm, Germany</aff>
<aff id="A3">
<label>3</label>Laboratory for Functional Genome Analysis, Gene Center, LMU München, 80539 Munich, Germany</aff>
<author-notes>
<corresp id="CR1">
<label>#</label>address correspondence to: Frank Kirchhoff, Phone: 49-731-50065150, Fax: 49-731-50065153, <email>frank.kirchhoff@uni-ulm.de</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>22</day>
<month>11</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="preprint">
<day>17</day>
<month>11</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">It has recently been shown that an early SARS-CoV-2 isolate (NL-02-2020) hijacks interferon-induced transmembrane proteins (IFITMs) for efficient replication in human cells. To date, several “Variants of Concern” (VOCs) showing increased infectivity and resistance to neutralization have emerged and globally replaced the early viral strains. Here, we determined whether the four SARS-CoV-2 VOCs (Alpha, Beta, Gamma and Delta) maintained the dependency on IFITM proteins for efficient replication. We found that depletion of IFITM2 strongly reduces viral RNA production by all four VOCs in the human epithelial lung cancer cell line Calu-3. Silencing of IFITM1 had little effect, while knock-down of IFITM3 resulted in an intermediate phenotype. Strikingly, depletion of IFITM2 generally reduced infectious virus production by more than four orders of magnitude. In addition, an antibody directed against the N-terminus of IFITM2 inhibited SARS-CoV-2 VOC replication in iPSC-derived alveolar epithelial type II cells thought to represent major viral target cells in the lung. In conclusion, endogenously expressed IFITM proteins (especially IFITM2) are critical cofactors for efficient replication of genuine SARS-CoV-2 VOCs, including the currently dominating Delta variant.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P2">Since its first occurrence in Wuhan (China) in December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has caused a devastating pandemic (<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref>). The reasons for the efficient spread of this coronavirus are not fully understood but clearly involve the ability to efficiently infect and propagate in human cells. Viral entry depends on binding of the viral Spike (S) protein to the cellular angiotensin-converting enzyme (ACE) 2 receptor and proteolytic processing of the S precursor into the active S1 and S2 subunits (<xref ref-type="bibr" rid="R3">3</xref>–<xref ref-type="bibr" rid="R5">5</xref>). However, additional host factors may affect the efficiency of SARS-CoV-2 entry and play roles in viral transmission and pathogenesis (<xref ref-type="bibr" rid="R6">6</xref>).</p>
<p id="P3">We recently demonstrated that interferon-inducible transmembrane proteins (IFITMs 1, 2, and 3) are required for efficient SARS-CoV-2 infection (<xref ref-type="bibr" rid="R7">7</xref>). This came as surprise since IFITMs are a family of IFN stimulated genes (ISGs) that are well-known to protect cells against infection by numerous viral pathogens including retro-, flavi-, influenza-, rhabdo-, filo- and bunyaviruses (<xref ref-type="bibr" rid="R3">3</xref>–<xref ref-type="bibr" rid="R5">5</xref>). Inhibitory effects have also been reported for highly pathogenic coronaviruses, including SARS-CoV-2 (<xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9">9</xref>). However, most evidence was obtained using pseudo-particles containing the S protein of SARS or MERS coronaviruses and/or cells that are not intrinsically permissve to this virus, artificially overexpress IFITM proteins and. Notably, it has been reported that the common cold coronavirus OC43 hijacks IFITM3 for efficient entry (<xref ref-type="bibr" rid="R10">10</xref>).</p>
<p id="P4">The antiviral mechanism of IFITMs is thought to involve alterations in the rigidity and curvature of the cellular membrane, affecting viruses in a broad, unspecific way (<xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R11">11</xref>). In contrast, the SARS-CoV-2 enhancing effect most likely involves specific interactions between the S protein and the N-terminal region of IFITMs, especially IFITM2 (<xref ref-type="bibr" rid="R7">7</xref>), suggesting that this pandemic viral pathogen hijacks IFITMs for efficient infection. In accordance with this knock-down of endogenous IFITM2 expression in human lung cell lines strongly reduced viral entry and infectious virus production. In addition, IFITM2-derived peptides as well as an IFITM2-targeting antibody protected gut organoids and cardiomyocytes against infection and cytopathic effects of SARS-CoV-2 (<xref ref-type="bibr" rid="R7">7</xref>).</p>
<p id="P5">In the initial study, IFITM dependency for efficient infection has only been demonstrated for an early European variant of SARS-CoV-2 isolated in the Netherlands in February 2020 (NL-02-2020) (<xref ref-type="bibr" rid="R7">7</xref>). Since then numerous variants have emerged. Some of them show increased transmission fitness and immune evasion and are thus referred to as “variants of concern” (VOCs). Currently, the WHO has categorized five SARS-CoV-2 variants as VOCs: B.1.1.7, B.1.351, P.1, B.1.617.2 and B.1.1.529. The first four, referred to as Alpha, Beta, Gamma and Delta variants, have significantly spread in the human population. The latest (Omicron) variant contains a worrisome number of mutations (<xref ref-type="bibr" rid="R12">12</xref>). However, it remains to be seen whether it might outcompete the Delta variant that currently dominates the pandemic and the Omicron variant was not yet Available for biological characterization. Compared to the NL-02-2020 isolate, all VOCs contain various alterations in their S proteins reported to enhance viral infectivity, transmissibility and pathogenicity by affecting ACE2 receptor affinity, proteolytic activation and susceptibility to neutralization (<xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R15">15</xref>). Here, we examined whether current SARS-CoV-2 VOCs still require IFITM proteins for efficient replication in human lung cells.</p>
</sec>
<sec id="S2" sec-type="results">
<title>Results</title>
<p id="P6">To verify that the SARS-CoV-2 VOCs show the expected differences in S compared to the early NL-02-2020 isolate, we performed full-genome sequence analyses of the four variants used for functional analyses. The NL-02-2020 isolate already contains the D614G amino acid substitution within the receptor-binding motif (RBM) which has been reported to increase SARS-CoV-2 transmissibility by promoting ACE2 receptor interaction and is also found in all current VOCs (<xref ref-type="bibr" rid="R16">16</xref>, <xref ref-type="bibr" rid="R17">17</xref>). As expected, the Spike proteins of the VOCs differed by six to ten amino acid changes from the NL-02-2020 Spike (<xref ref-type="fig" rid="F1">Figure 1</xref>). The Alpha VOC (B.1.1.7) that emerged at the end of 2020 in the UK contains eight mutations in its S protein: Deletion of H69/V70 and Y144; Mutation of N501Y, A570D, P681H, T716I, S982A and D1118H (<xref ref-type="bibr" rid="R18">18</xref>). The Beta VOC (B.1.351) emerged in South Africa in October 2020 and has initially spread to all continents (<xref ref-type="bibr" rid="R19">19</xref>). Its S protein contains three alterations in the RBD (K417N, E484K, N501Y) and five additional changes (L18F, D80A, D215G, R246I, A701V). The Gamma (P.1) variant was first detected in Brazil at the end of 2020 and shares the K417T, E484K and N501Y S mutations with the Alpha and/or Beta VOCs (<xref ref-type="fig" rid="F1">Figure 1</xref>) (<xref ref-type="bibr" rid="R20">20</xref>). The Delta (B.1.617.2) variant was first identified in India in the first half of 2021 (<xref ref-type="bibr" rid="R21">21</xref>) and has efficiently outcompeted all other SARS-CoV-2 VOCs around the globe. It differs by changes of T19R, deletion of residues 157-158, L452R, T478K, E484K, P681R, R683L and D950N from NL-02-2020 in the S protein (<xref ref-type="fig" rid="F1">Figure 1</xref>). Several changes (L18F, K417T, E484K and N501Y) emerged independently by convergent evolution in several VOCs (<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R22">22</xref>). The reasons why they are associated with a selective advantage remain to be fully elucidated but rapidly accumulating evidence shows they reduce neutralization by antibodies and/or increase ACE2 binding affinity (<xref ref-type="bibr" rid="R14">14</xref>). In addition, the P681R substitution near the furin cleavage site might improve proteolytic activation of the Delta S protein (<xref ref-type="bibr" rid="R23">23</xref>, <xref ref-type="bibr" rid="R24">24</xref>). Thus, all VOCs contain changes in their S proteins reported to increase interaction with their primary ACE2 receptor that might also affect the dependency on other cellular cofactors for efficient entry and fusion, like IFITM proteins.</p>
<p id="P7">To examine the role of endogenous IFITM expression on infection by genuine SARS-CoV-2 VOCs, we performed siRNA knockdown (KD) studies in the human epithelial lung cancer cell line Calu-3, which endogenously express ACE2 and all three IFITM proteins (<xref ref-type="bibr" rid="R7">7</xref>). Viral replication was determined by quantification of viral N (nucleocapsid) RNA levels by qRT-PCR in the cell culture supernatants 2 days after infection with the five SARS-CoV-2 variants (<xref ref-type="fig" rid="F2">Figure 2A</xref>). Most VOCs produced 2- to 4-fold higher levels of viral RNA compared to NL-02-2020 in Calu-3 cells (<xref ref-type="fig" rid="F2">Figure 2B</xref>). The single exception was the Beta variant, which showed moderately lower levels of viral RNA production. Silencing of IFITM2 expression reduced viral RNA production from 31- (Alpha) to 754-fold (Gamma). Replication of the Beta variant was 112x reduced in the absence of IFITM2, respectively. In comparison, KD of IFITM1 had little effect, while silencing of IFITM3 resulted in 2- (Beta) to a maximum of 31-fold (NL-02-2020) lower viral RNA yields (<xref ref-type="fig" rid="F2">Figure 2B</xref>). Notably, IFITM2 KD still reduced viral RNA yields by the currently dominant Delta variant by &gt;100-fold, while IFITM3 silencing was associated with a 20-fold reduction, demonstrating that this VOC still requires IFITM proteins for efficient entry.</p>
<p id="P8">To further determine whether IFITM2 is critical for productive replication of SARS-CoV-2 VOCs in Calu-3 cells, we determined the TCID<sub>50</sub> (50% Tissue Culture Infectious Dose) of viral particles in the cell culture supernatants (<xref ref-type="fig" rid="F3">Figure 3A</xref>). With the exception of the Beta variant that showed the lowest viral RNA yields (<xref ref-type="fig" rid="F2">Figure 2</xref>) and infectious titers, all SARS-CoV-2 variants produced more than 10 million infectious virus particles per ml culture supernatant in Calu-3 cells treated with the control siRNA (<xref ref-type="fig" rid="F3">Figure 3B</xref>). In striking contract, infectious virus production was generally reduced to levels near or below background (≤100 infectious particles per ml) upon silencing of IFITM2 (<xref ref-type="fig" rid="F3">Figure 3</xref>). Altogether, these results show that all four SARS-CoV-2 VOCs including the dominant Delta variants are strongly dependent on endogenous IFITM2 expression for efficient replication in Calu-3 cells.</p>
<p id="P9">We have previously shown that an antibody targeting the N-terminus of IFITM2 inhibits replication of the NL-02-2020 isolate in gut organoids and cardiomyocytes (<xref ref-type="bibr" rid="R7">7</xref>). To further examine the potential relevance of IFITM2 for transmission of SARS-CoV-2 VOCs, we performed experiments in iPSC-derived alveolar epithelial type II (iATII) cells, as a model for the main target cells of SARS-CoV-2 infection in the distal lung (<xref ref-type="bibr" rid="R25">25</xref>). Western blot analyses showed that, similarly to Calu-3 cells, iATII cells express IFITM2 and IFITM3 (<xref ref-type="fig" rid="F4">Figure 4A</xref>). In contrast, both cells types showed little (Calu-3) or no (iATII) detectable expression of IFITM1. Unexpectedly, we did not detect ACE2 expression in iATII cells by western blot analyses while ACE2 was readily detectable in Calu-3 cells (<xref ref-type="fig" rid="F4">Figure 4A</xref>). In agreement with published data (<xref ref-type="bibr" rid="R26">26</xref>), however, ACE2 expression by iATII cells was clearly detectable by FACS (<xref ref-type="fig" rid="F4">Figure 4B</xref>).</p>
<p id="P10">In agreement with published data (<xref ref-type="bibr" rid="R26">26</xref>–<xref ref-type="bibr" rid="R28">28</xref>), iATII cells were highly susceptible to SARS-CoV-2 replication and typically produced about 100-fold higher levels of viral RNA compared to Calu-3 cells (<xref ref-type="fig" rid="F2">Figures 2B</xref>, <xref ref-type="fig" rid="F5">5A</xref>). On average, the Delta variant replicated to about 30-fold higher levels (average vRNA copy numbers of 2.4×10<sup>11</sup>) than the early NL-02-2020 isolate in iATII cells (<xref ref-type="fig" rid="F5">Figure 5A</xref>). The broad-spectrum antiviral agent Remdesivir (<xref ref-type="bibr" rid="R29">29</xref>) efficiently inhibited replication of all SARS-CoV-2 variants. Treatment of iATII cells with the antibody against the N-terminus of IFITM2 also generally reduced viral RNA production in a dose-dependent manner, albeit varying efficiencies. Most notably, the anti-IFITM2 Ab reduced replication of the Delta VOC in iATII cells by up to 95% (<xref ref-type="fig" rid="F5">Figure 5B</xref>). This agrees with our previous finding that IFITM2 can be targeted to protect various types of human cells against SARS-CoV-2 infection (<xref ref-type="bibr" rid="R7">7</xref>).</p>
</sec>
<sec id="S3" sec-type="discussion">
<title>Discussion</title>
<p id="P11">In the present study, we demonstrate that IFITMs (especially IFITM2) are also critical cofactors for efficient replication of all four SARS-CoV-2 VOCs including the currently dominant Delta variant. We have previously shown that IFITMs also promote SARS-CoV-2 replication in primary small airway epithelial cells (SAEC) cells and that IFITM2 can be targeted to inhibit viral replication in gut organoids and cardiomyocytes derived from human iPSCs (<xref ref-type="bibr" rid="R7">7</xref>). The present finding that an α-IFITM2 antibody inhibits replication of the Delta variants in iPSC-derived alveolar epithelial type II cells, proposed to model main target cells of SARS-CoV-2 infection in the distal lung (<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R28">28</xref>), adds to the evidence that IFITM2 may play a key role in SARS-CoV-2 transmission, dissemination and pathogenesis. Our observation that IFITM2 dependency is maintained by VOCs also further underlines that against the odds this cellular “antiviral” factor represents a target for therapeutic or preventive approaches.</p>
<p id="P12">In agreement with previous findings (<xref ref-type="bibr" rid="R23">23</xref>, <xref ref-type="bibr" rid="R30">30</xref>), the Delta variant replicated with higher efficiency than the early SARS-CoV-2 isolate in human lung cells particularly in iPSC-derived alveolar epithelial type II cells. This agrees with recent data showing that the Delta variant infects human bronchial epithelial cells with higher efficiency than other VOCs (<xref ref-type="bibr" rid="R31">31</xref>). Altogether, our results show that IFITMs (especially IFITM2) are also critical cofactors for efficient replication of all four current SARS-CoV-2 VOCs. Notably, however, the Alpha variant yielded ~100-fold higher levels of vRNA upon silencing of IFITM2 expression compared to the 2019 CoV-2 and Beta variants (<xref ref-type="fig" rid="F2">Figure 2</xref>). Thus, it is tempting to speculate that this VOC did not only evolve reduced susceptibility to IFN inhibition (<xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R32">32</xref>) but may also dependent less on IFITM2 for efficient infection compared to other SARS-CoV-2 variants.</p>
<p id="P13">The exact mechanism of IFITM2-dependent enhancement needs further studies. However, our previous studies suggest that IFITM2 promotes SARS-CoV-2 entry by direct interaction with the viral Spike protein and enhancing virus-cell fusion in early endosomes (<xref ref-type="bibr" rid="R7">7</xref>). The enhancing effect is only observed for genuine SARS-CoV-2 and endogenous IFITMs, while the broad antiviral activity of IFITMs involving alterations in cellular membrane rigidity and curvature instead of specific interactions with viral glycoproteins has been reported for pseudovirions carrying SARS-CoV-2 Spike proteins and for overexpression of IFITM proteins (<xref ref-type="bibr" rid="R8">8</xref>). In agreement with our previous results (<xref ref-type="bibr" rid="R7">7</xref>), IFITM2 KD had stronger effects on infectious titers than on viral RNA yields. It remains to be determined whether the presence of IFITM2 has indeed an enhancing effect on the infectiousness of SARS-CoV-2 particles or if the background levels are just higher for viral RNA due to release from or lysis of infected cells.</p>
<p id="P14">The Alpha and Delta variants contain a mutation P681H/R close to the furin cleavage site that might affect interferon sensitivity, proteolytic activation and fusogenicity of the S protein (<xref ref-type="bibr" rid="R33">33</xref>, <xref ref-type="bibr" rid="R34">34</xref>). These two VOCs produced the highest levels of viral RNA upon IFITM2 KD and it will be interesting to further examine whether an increased intrinsic fusogenic activity of the Alpha and Delta Spike proteins affects their dependency on IFITM2 for infection.</p>
<p id="P15">Our results are further evidence that IFITM proteins are critical cofactors for infection of SARS-CoV-2 in primary human target cells. We show that an α-IFITM2 antibody inhibits replication of the Delta VOC in human alveolar epithelial type II cells by &gt;90% (<xref ref-type="fig" rid="F5">Figure 5B</xref>) reported to play a key role in the spread of SARS-CoV-2. This finding further suggests that IFITM2 may be a highly unexpected suitable target for therapeutic approaches against this pandemic viral pathogen. It will be interesting to determine whether the emerging Omicron variant that contains a striking number of about 30 amino acid changes in the Spike protein compared to the Wuhan strain (<xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R35">35</xref>) is also dependent on IFITM2 for efficient infection and susceptible to inhibition by α-ITITM2 antibodies.</p>
</sec>
<sec id="S4" sec-type="materials | methods">
<title>Material and Methods</title>
<sec id="S5">
<title>Cell culture</title>
<p id="P16">Calu-3 (human epithelial lung adenocarcinoma) cells were cultured in Minimum Essential Medium Eagle (MEM, Sigma, Cat#M4655) supplemented with 10% (upon and after viral infection) or 20% (during all other times) heat-inactivated fetal bovine serum (FBS, Gibco, Cat#10270106), 100 units/ml penicillin, 100 μg/ml streptomycin (ThermoFisher, Cat#15140122), 1 mM sodium pyruvate (Pan Biotech, Cat#P04-8010), and 1x non-essential amino acids (Sigma, Cat#M7145). Vero E6 cells (Cercopithecus aethiops derived epithelial kidney, ATCC) and TMPRSS2-expressing Vero E6 cells (kindly provided by the National Institute for Biological Standards and Control (NIBSC), No. 100978) were grown in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Cat#41965039) supplemented with 2.5% (upon and after viral infection) or 10% (during all other times) heat-inactivated FBS (Gibco, Cat#10270106), 100 units/ml penicillin, 100 μg/ml streptomycin (ThermoFisher, Cat#15140122), 2 mM L-glutamine (Gibco, Cat#25030081), 1 mM sodium pyruvate (Pan Biotech, Cat# P04-8010), 1x non-essential amino acids (Sigma, Cat#M7145) and 1 mg/mL Geneticin (Gibco, Cat#10131-019) (for TMPRSS2-expressing Vero E6 cells). Caco-2 cells (human epithelial colorectal adenocarcinoma, kindly provided by Prof. Holger Barth (Ulm University)) were grown in the same media as Vero E6 cells but with supplementation of 10% heat-inactivated FBS.</p>
<p id="P17">Human induced Alveolar Type 2 cells (iATII) were differentiated from BU3 NKX2-1<sup>GFP</sup>;SFTPC<sup>tdTomato</sup> induced pluripotent stem cells(<xref ref-type="bibr" rid="R36">36</xref>) (iPCSs, kindly provided by Darrell Kotton, Boston University and Boston Medical Center) and maintained as alveolospheres embedded in 3D Matrigel in CK+DCI media, as previously described(<xref ref-type="bibr" rid="R37">37</xref>). For infection studies, iATII cells were cultured as 2D cultures on Matrigel-coated plates in CK+DCI medium + 10 μM Y-27632 (Tocris, Cat#1254) for 48h before switching to CK+DCI medium on day 3.</p>
</sec>
<sec id="S6">
<title>SARS-CoV-2 stocks</title>
<p id="P18">The SARS-CoV-2 variant B.1.351 (Beta), 2102-cov-IM-r1-164 was provided by Prof. Michael Schindler (University of Tübingen) and the B.1.617.2 (Delta) variant by Prof. Florian Schmidt (University of Bonn). The BetaCoV/Netherlands/01/NL/2020 (NL-02-2020) and B.1.1.7. (Alpha) variants were obtained from the European Virus Archive. The hCoV-19/Japan/TY7-503/2021 (Brazil P.1) (Gamma) (#NR-54982) isolate was obtained from the BEI resources. SARS-CoV-2 strains were propagated on Vero E6 (NL-02-2020, Delta), VeroE6 overexpressing TMPRSS2 (Alpha), CaCo-2 (Beta) or Calu-3 (Gamma) cells. To this end, 70-90% confluent cells in 75 cm<sup>2</sup> cell culture flasks were inoculated with the SARS-CoV-2 isolate (multiplicity of infection (MOI) of 0.03-0.1) in 3.5 ml serum-free medium. The cells were incubated for 2h at 37°C, before adding 20 ml medium containing 15 mM HEPES (Carl Roth, Cat#6763.1). Virus stocks were harvested as soon as strong cytopathic effect (CPE) became apparent. The virus stocks were centrifuged for 5 min at 1,000 g to remove cellular debris, aliquoted, and stored at -80°C until further use.</p>
</sec>
<sec id="S7">
<title>Sequencing of SARS-CoV-2 VOCs</title>
<p id="P19">Virus stocks were inactivated and lysed by adding 0.3 ml TRIzol Reagent (ambion, Cat#132903) to 0.1 ml virus stock. Viral RNA was isolated using the Direct-zol RNA MiniPrep kit (ZymoResearch, Cat#R2050) according to manufacturer’s instructions, eluting the RNA in 50 μl DNase/RNase free water. The protocol to prepare the viral RNA for sequencing was modified from the nCoV-2019 sequencing protocol V.1. For reverse transcription, the SuperScript IV First-Strand Synthesis System (Invitrogen, Cat#18091050) was used with modified manufacturer’s instructions. First, 1 μl random hexamers (50 ng/μl), 1 μl dNTPs mix (10 mM each), and 11 μl template RNA (diluted 1:10 in DNase/RNase free water) were mixed, incubated at 65°C for 5 min and placed on ice for 1 min. Next, 4 μl SSIV Buffer, 1 μl DTT (100 mM), 1 μl RNaseOUT RNase Inhibitor, and 1 μl SSIV Reverse Transcriptase were added to the mix, followed by incubation at 24°C for 5 min, 42°C for 50 min, and 70°C for 10 min. To generate 400 nt fragments in PCR, the ARTIC nCoV-2019 V3 Primer set (IDT) and the Q5 Hot Start High-Fidelity 2X Master Mix (NEB, Cat#M0494S) were used with modified manufacturer’s instructions. The primers pools 1 and 2 were diluted to a final concentration of 10 μM and a reaction with each primer pool was set up as follows, 4 μl respective primer pool, 12.5 μl Q5 Hot Start High-Fidelity 2X Master Mix, 6 μl water, and 2.5 μl cDNA. The PCR was performed as follows, 98°C for 30 s, 30 cycles of 98°C for 15 s and 65°C for 5 min, and hold at 4°C. The PCR products were run on a 1% agarose gel to check for the presence of fragments at the correct size. The products from primer pool 1 and primer pool 2 for each variant were pooled, diluted and quantified by Qubit DNA HS kit (Thermo Fisher, Cat#Q32851). The sequencing amplicon pools were diluted to 0.2 ng/μl and tagmented with Nextera XT library prep kit (Illumina, Cat#FC-131-1024). Nextera libraries were dual-barcoded and sequenced on an Illumina NextSeq1000 instrument. The obtained sequenced reads were demultiplexed and mapped against the SARS-CoV-2 reference genome (NC_045512.2) with <italic>BWA-MEM</italic>(<xref ref-type="bibr" rid="R38">38</xref>). Pileup files were generated from the mapped reads using <italic>Samtools(<xref ref-type="bibr" rid="R39">39</xref>).</italic> The mapped reads and the pileup file were used to construct the consensus sequence with the <italic>iVar</italic> package (<xref ref-type="bibr" rid="R40">40</xref>) using default settings.</p>
</sec>
<sec id="S8">
<title>IFITM knock-down</title>
<p id="P20">At 24 h and 96 h post-seeding, 150,000 Calu-3 cells, seeded in 24-well plates, were transfected with 20 μM of non-targeting siRNA or IFITM1, IFITM2 or IFITM3 specific siRNAs using Lipofectamine RNAiMAX (Thermo Fisher, Cat#13778100) according to the manufacturer’s instructions. 6 h after the second transfection, Calu-3 cells were infected with the various SARS-CoV-2 variants at an MOI of 0.05. 6 h post-infection, the inoculum was removed, the cells washed once with PBS and supplemented with fresh media. 48 h post infection, supernatants were harvested for qRT-PCR analysis.</p>
</sec>
<sec id="S9">
<title>qRT-PCR</title>
<p id="P21">
<italic>N</italic> (nucleoprotein) transcript levels were determined in supernatants collected from SARS-CoV-2 infected Calu-3 cells 48 h post-infection as previously described(<xref ref-type="bibr" rid="R41">41</xref>). Total RNA was isolated using the Viral RNA Mini Kit (Qiagen, Cat#52906) according to the manufacturer’s instructions. RT-qPCR was performed as previously described(<xref ref-type="bibr" rid="R42">42</xref>) using TaqMan Fast Virus 1-Step Master Mix (Thermo Fisher, Cat#4444436) and a OneStepPlus Real-Time PCR System (96-well format, fast mode). Primers were purchased from Biomers (Ulm, Germany) and dissolved in RNAse free water. Synthetic SARS-CoV-2-RNA (Twist Bioscience, Cat#102024) or RNA isolated from BetaCoV/France/IDF0372/2020 viral stocks quantified via this synthetic RNA (for low Ct samples) were used as a quantitative standard to obtain viral copy numbers. All reactions were run in duplicates. Forward primer (HKU-NF): 5’-TAA TCA GAC AAG GAA CTG ATT A-3’; Reverse primer (HKU-NR): 5’-CGA AGG TGT GAC TTC CAT G-3’; Probe (HKU-NP): 5’-FAM-GCA AAT TGT GCA ATT TGC GG-TAMRA-3’.</p>
</sec>
<sec id="S10">
<title>Inhibition by IFITM2 antibody and Remdesivir</title>
<p id="P22">30,000 iATII cells were seeded as single cells in 96-well plates coated for 1 h at 37 °C with 0.16 mg/ml Matrigel (Corning, Cat#356238) diluted in DMEM/F12 (Thermo Fisher, Cat#11330032), 24 h later cells were treated with increasing concentrations (20, 40, 80 μg/ml) of α-IFITM2 (Cell Signaling, Cat#13530 S) or Remdesivir (Selleck Chemicals Cat#S8932) (10 μM). One h post-treatment, cells were infected with SARS-CoV-2 VOCs with a MOI of 0.5. 6 h post-infection, cells were washed once with PBS and supplemented with fresh medium. Thereafter, day 0 wash CTRL was harvested. 48 h post-infection supernatants were harvested for qRT-PCR analysis.</p>
</sec>
<sec id="S11">
<title>Western blot</title>
<p id="P23">To determine the expression of cellular and viral proteins, infected Calu-3 (MOI 0.2, 48 h post infection) or iATII (MOI 0.5, 48 h post infection) cells or uninfected controls were washed in PBS and subsequently lysed in Western blot lysis buffer (150 mM NaCl, 50 mM HEPES, 5 mM EDTA, 0.1% NP40, 500 μM Na3VO4, 500 μM NaF, pH 7.5) supplemented with protease inhibitor cocktail (Roche, Cat#11697498001). After 5 min of incubation on ice, samples were centrifuged (4 °C, 20 min, 20,817 g) to remove cell debris. The supernatant was transferred to a fresh tube, the protein concentration was measured by Nanodrop and adjusted using Western blot lysis buffer. Western blotting was performed as previously reported. Proteins were stained using primary antibodies against IFITM1 (α-IFITM1, Cell Signaling Cat#13126S, 1:1,000), IFITM2 (α-IFITM2 Cell Signaling Cat#13530 S, 1:1,000), IFITM3 (α-IFITM3 Cell Signaling Cat#59212S, 1:1,000), ACE2 (Rabbit polyclonal anti-ACE2 Abcam, Cat#ab166755, 1:1,000); rat anti-GAPDH (Biolegend Cat#607902, 1:1,000) and SARS CoV-2 N (anti-SARS-CoV-2 N Sino Biologicals Cat#40588-V08B, 1:1,000) and Infrared Dye labeled secondary antibodies (LI-COR IRDye). Membranes were scanned using an Odyssey infrared imager and band intensities were quantified in Image Studio Lite Version 5.0.</p>
</sec>
<sec id="S12">
<title>TCID<sub>50</sub> Endpoint titration</title>
<p id="P24">10,000 Caco-2 cells were seeded in 96-well F-bottom plates. One day later, infectious supernatants were serially diluted and added to the cells. Cells were then incubated for 5 days and monitored for CPE. TCID<sub>50</sub>/mL was calculated according to Reed and Muench.</p>
</sec>
<sec id="S13">
<title>Flow cytometric analysis</title>
<p id="P25">60,000 iATII cells or Calu-3 cells were incubated for 1 h at 4°C with equal protein concentrations of control rabbit IgG (Diagenode, Cat#C15410206) or 1/200 dilution of rabbit anti-ACE2 (Abcam, Cat#ab166755) diluted in FACS buffer (PBS, 1% FBS), washed three times in PBS, stained for 30 min with 1/400 dilution of goat anti-rabbit AF647 (Invitrogen, Cat#A27040), fixed in 1% PFA and analyzed using a BD FACS Canto II flow cytometer.</p>
</sec>
<sec id="S14">
<title>Statistical analysis</title>
<p id="P26">Statistical analysis was performed using GraphPad Prism software. Two-tailed unpaired Student’s t-test were used to determine statistical significance. Significant differences are indicated as: *, p &lt; 0.05; **, p &lt; 0.01; ***, p &lt; 0.001; **** p&lt;0.0001. Statistical parameters are specified in the figure legends.</p>
</sec>
</sec>
</body>
<back>
<ack id="S15">
<title>Acknowledgments</title>
<p>We thank Daniela Krnavek, Martha Mayer, Kerstin Regensburger, Regina Burger, Jana Romana Fischer and Birgit Ott for laboratory assistance. We also thank Stefan Krebs, Helmut Blum, Alexander Graf for next generation sequencing of SARS-CoV-2 VOCs, Michael Schindler for providing the B.1.351 (Beta) VOC and Florian Schmidt, Beate M. Kümmerer and Hendrick Streeck for providing the B.1.617.2 (Delta) VOC. The following reagent was obtained through BEI Resources, NIAID, NIH: SARS-CoV-2, Isolate hCoV-19/Japan/TY7-503/2021 (Brazil P.1), NR-54982, contributed by National Institute of Infectious Diseases.</p>
<sec id="S16">
<title>Funding</title>
<p>This study was supported by DFG grants to F.K. (CRC 1279) and K.M.J.S. (CRC 1279, SP1600/6-1), the BMBF to F.K. and K.M.J.S. (Restrict SARS-CoV-2, and IMMUNOMOD) and a COVID-19 research grant from the Ministry of Science, Research and the Arts of Baden-Württemberg (MWK) to F.K. A.S. and M.F. were supported by the DFG (project numbers 278012962 &amp; 458685747). The BU3-NGST iPSC line was generated with funding from the National Center for Advancing Translational Sciences (”NCATS”) (grant U01TR001810) and kindly provided by D.N. Kotton (Center for Regenerative Medicine, Boston Medical Center).</p>
</sec>
</ack>
<fn-group>
<fn id="FN1" fn-type="con">
<p id="P27">
<bold>Authors Information</bold>
</p>
<p id="P28">Conceptualization and funding acquisition, F.K., K.M.J.S., M.F.; Investigation, R.N., C.P.B., F.Z., L.K., D.K. and A. S.; Writing, F.K.; Review and editing, all authors.</p>
</fn>
<fn id="FN2" fn-type="conflict">
<p id="P29">
<bold>Competing Interests</bold>
</p>
<p id="P30">The authors declare no competing interests.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>XL</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>XG</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Si</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>HD</given-names>
</name>
<etal/>
</person-group>
<article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>
<source>Nature</source>
<year>2020</year>
<volume>579</volume>
<fpage>270</fpage>
<lpage>273</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>A Novel Coronavirus from Patients with Pneumonia in China, 2019</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<volume>382</volume>
<fpage>727</fpage>
<lpage>733</lpage>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bailey</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>I-C</given-names>
</name>
<name>
<surname>Farzan</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>IFITM-Family Proteins: The Cell’s First Line of Antiviral Defense</article-title>
<source>Annual Review of Virology</source>
<year>2014</year>
<volume>1</volume>
<fpage>261</fpage>
<lpage>283</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Diamond</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Farzan</surname>
<given-names>M</given-names>
</name>
</person-group>
<source>The broad-spectrum antiviral functions of IFIT and IFITM proteinsNature Reviews Immunology</source>
<publisher-name>Nature Publishing Group</publisher-name>
<year>2013</year>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>An</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>JT</given-names>
</name>
</person-group>
<article-title>IFITM genes, variants, and their roles in the control and pathogenesis of viral infectionsFrontiers in Microbiology</article-title>
<source>Frontiers Media S.A</source>
<year>2019</year>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baggen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vanstreels</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Jansen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Daelemans</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Cellular host factors for SARS-CoV-2 infection</article-title>
<source>Nat Microbiol</source>
<year>2021</year>
<volume>6</volume>
<fpage>1219</fpage>
<lpage>1232</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prelli Bozzo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nchioua</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Volcic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Koepke</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Krüger</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schütz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Heller</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stürzel</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Kmiec</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Conzelmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<elocation-id>4584</elocation-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kenney</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Kudryashova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Hall-Stoodley</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Kudryashov</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Compton</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Yount</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Opposing activities of IFITM proteins in SARS-CoV-2 infection</article-title>
<source>EMBO J</source>
<year>2020</year>
<elocation-id>e106501</elocation-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wrensch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pöhlmann</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>IFITM proteins inhibit entry driven by the MERS-Coronavirus Spike protein: Evidence for Cholesterol-Independent Mechanisms</article-title>
<source>Viruses</source>
<year>2014</year>
<volume>6</volume>
<fpage>3683</fpage>
<lpage>3698</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cuconati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Block</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>JT</given-names>
</name>
</person-group>
<article-title>Interferon induction of IFITM proteins promotes infection by human coronavirus OC43</article-title>
<source>Proceedings of the National Academy of Sciences of the United States of America</source>
<year>2014</year>
<volume>111</volume>
<fpage>6756</fpage>
<lpage>6761</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Compton</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Bruel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Porrot</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mallet</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sachse</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Euvrard</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Casartelli</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread</article-title>
<source>Cell Host and Microbe</source>
<year>2014</year>
<volume>16</volume>
<fpage>736</fpage>
<lpage>747</lpage>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="other">
<source>Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern</source>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soh</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>US</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H-R</given-names>
</name>
</person-group>
<article-title>The rapid adaptation of SARS-CoV-2-rise of the variants: transmission and resistance</article-title>
<source>J Microbiol</source>
<year>2021</year>
<volume>59</volume>
<fpage>807</fpage>
<lpage>818</lpage>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harvey</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Carabelli</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Harrison</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Ludden</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Reeve</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rambaut</surname>
<given-names>A</given-names>
</name>
<collab>COVID-19 Genomics UK (COG-UK) Consortium</collab>
<name>
<surname>Peacock</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>SARS-CoV-2 variants, spike mutations and immune escape</article-title>
<source>Nat Rev Microbiol</source>
<year>2021</year>
<volume>19</volume>
<fpage>409</fpage>
<lpage>424</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Genovese</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zaccaria</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Farzan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Momeni</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Investigating the mutational landscape of the SARS-CoV-2 Omicron variant via ab initio quantum mechanical modeling</article-title>
<year>2021</year>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korber</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Gnanakaran</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yoon</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Theiler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Abfalterer</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hengartner</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Giorgi</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Bhattacharya</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Foley</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hastie</surname>
<given-names>KM</given-names>
</name>
<etal/>
</person-group>
<article-title>Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>812</fpage>
<lpage>827</lpage>
<elocation-id>e19</elocation-id>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yurkovetskiy</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Pascal</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Tomkins-Tinch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nyalile</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Baum</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Diehl</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Dauphin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Carbone</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Veinotte</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>
<article-title>Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant</article-title>
<source>Cell</source>
<year>2020</year>
<volume>183</volume>
<fpage>739</fpage>
<lpage>751</lpage>
<elocation-id>e8</elocation-id>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borges</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sousa</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Menezes</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gonçalves</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Picão</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Vieita</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Santos</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carneiro</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Tracking SARS-CoV-2 lineage B.1.1.7 dissemination: insights from nationwide spike gene target failure (SGTF) and spike gene late detection (SGTL) data, Portugal, week 49 2020 to week 3 2021</article-title>
<source>Euro Surveill</source>
<year>2021</year>
<fpage>26</fpage>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tegally</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Giovanetti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Iranzadeh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fonseca</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Giandhari</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Doolabh</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pillay</surname>
<given-names>S</given-names>
</name>
<name>
<surname>San</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Msomi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mlisana</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>
<article-title>Detection of a SARS-CoV-2 variant of concern in South Africa</article-title>
<source>Nature</source>
<year>2021</year>
<volume>592</volume>
<fpage>438</fpage>
<lpage>443</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faria</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Mellan</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Whittaker</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Claro</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Candido</surname>
<given-names>D</given-names>
</name>
<name>
<surname>da</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mishra</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Crispim</surname>
<given-names>MAE</given-names>
</name>
<name>
<surname>Sales</surname>
<given-names>FCS</given-names>
</name>
<name>
<surname>Hawryluk</surname>
<given-names>I</given-names>
</name>
<name>
<surname>McCrone</surname>
<given-names>JT</given-names>
</name>
<etal/>
</person-group>
<article-title>Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil</article-title>
<source>Science</source>
<year>2021</year>
<volume>372</volume>
<fpage>815</fpage>
<lpage>821</lpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheikh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McMenamin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>C</given-names>
</name>
</person-group>
<collab>Public Health Scotland and the EAVE II Collaborators</collab>
<article-title>SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness</article-title>
<source>Lancet</source>
<year>2021</year>
<volume>397</volume>
<fpage>2461</fpage>
<lpage>2462</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tegally</surname>
<given-names>H</given-names>
</name>
<name>
<surname>San</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Shank</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lucaci</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Giandhari</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Naidoo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pillay</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>5189</fpage>
<lpage>5200</lpage>
<elocation-id>e7</elocation-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mlcochova</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kemp</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Dhar</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Papa</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>IATM</given-names>
</name>
<name>
<surname>Datir</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Collier</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Albecka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pandey</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion</article-title>
<source>Nature</source>
<year>2021</year>
<volume>599</volume>
<fpage>114</fpage>
<lpage>119</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cherian</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Potdar</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Jadhav</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yadav</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rakshit</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Panda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Team</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India</article-title>
<source>Microorganisms</source>
<year>2021</year>
<volume>9</volume>
<elocation-id>1542</elocation-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delorey</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Ziegler</surname>
<given-names>CGK</given-names>
</name>
<name>
<surname>Heimberg</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Normand</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Segerstolpe</surname>
<given-names>Å</given-names>
</name>
<name>
<surname>Abbondanza</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fleming</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Subramanian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Montoro</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Jagadeesh</surname>
<given-names>KA</given-names>
</name>
<etal/>
</person-group>
<article-title>COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets</article-title>
<source>Nature</source>
<year>2021</year>
<volume>595</volume>
<fpage>107</fpage>
<lpage>113</lpage>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hume</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Abo</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Werder</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Villacorta-Martin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Alysandratos</surname>
<given-names>K-D</given-names>
</name>
<name>
<surname>Beermann</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Simone-Roach</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lindstrom-Vautrin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Olejnik</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Suder</surname>
<given-names>EL</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response</article-title>
<source>Cell Stem Cell</source>
<year>2020</year>
<volume>27</volume>
<fpage>962</fpage>
<lpage>973</lpage>
<elocation-id>e7</elocation-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Vaart</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lamers</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Haagmans</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Clevers</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Advancing lung organoids for COVID-19 research</article-title>
<source>Dis Model Mech</source>
<year>2021</year>
<volume>14</volume>
<elocation-id>dmm049060</elocation-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abo</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Matte</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Alysandratos</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Werder</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Mithal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Beermann</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Lindstrom-Vautrin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mostoslavsky</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ikonomou</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Human iPSC-derived alveolar and airway epithelial cells can be cultured at air-liquid interface and express SARS-CoV-2 host factors</article-title>
<source>bioRxiv</source>
<year>2020</year>
<elocation-id>2020.06.03.132639</elocation-id>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krüger</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Groß</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Conzelmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Koepke</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sparrer</surname>
<given-names>KMJ</given-names>
</name>
<name>
<surname>Schütz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Seufferlein</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Barth</surname>
<given-names>TFE</given-names>
</name>
<name>
<surname>Stenger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Heller</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Remdesivir but not famotidine inhibits SARS-CoV-2 replication in human pluripotent stem cell-derived intestinal organoids</article-title>
<source>bioRxiv</source>
<year>2020</year>
<elocation-id>2020.06.10.144816</elocation-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nchioua</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schundner</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Klute</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Noettger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zech</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Koepke</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Graf</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krebs</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Blum</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kmiec</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Frick</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>The Delta variant of SARS-CoV-2 maintains high sensitivity to interferons in human lung cells</article-title>
<year>2021</year>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>SARS-CoV-2 Delta variant infects ACE2low primary human bronchial epithelial cells more efficiently than other variants</article-title>
<source>Journal of Medical Virology n/a</source>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thorne</surname>
<given-names>LG</given-names>
</name>
<name>
<surname>Bouhaddou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Reuschl</surname>
<given-names>A-K</given-names>
</name>
<name>
<surname>Zuliani-Alvarez</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Polacco</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pelin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Batra</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Whelan</surname>
<given-names>MVX</given-names>
</name>
<name>
<surname>Ummadi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rojc</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant</article-title>
<year>2021</year>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peacock</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Sheppard</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Goonawardane</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Whiteley</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Consortium</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>de Silva</surname>
<given-names>TI</given-names>
</name>
<name>
<surname>Barclay</surname>
<given-names>WS</given-names>
</name>
</person-group>
<article-title>The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin</article-title>
<year>2021</year>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ku</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Schindewolf</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Widen</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>An</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Menachery</surname>
<given-names>VD</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>P-Y</given-names>
</name>
</person-group>
<article-title>Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant</article-title>
<source>bioRxiv</source>
<year>2021</year>
<elocation-id>2021.08.12.456173</elocation-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Thambiraja</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Karuppanan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Subramaniam</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Omicron and Delta Variant of SARS-CoV-2: A Comparative Computational Study of Spike protein</article-title>
<year>2021</year>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacob</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Morley</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hawkins</surname>
<given-names>F</given-names>
</name>
<name>
<surname>McCauley</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Jean</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Heins</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Na</surname>
<given-names>C-L</given-names>
</name>
<name>
<surname>Weaver</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Vedaie</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hurley</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hinds</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Differentiation of Human Pluripotent Stem Cells into Functional Lung Alveolar Epithelial Cells</article-title>
<source>Cell Stem Cell</source>
<year>2017</year>
<volume>21</volume>
<fpage>472</fpage>
<lpage>488</lpage>
<elocation-id>e10</elocation-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacob</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vedaie</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Villacorta-Martin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Alysandratos</surname>
<given-names>K-D</given-names>
</name>
<name>
<surname>Hawkins</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kotton</surname>
<given-names>DN</given-names>
</name>
</person-group>
<article-title>Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells</article-title>
<source>Nat Protoc</source>
<year>2019</year>
<volume>14</volume>
<fpage>3303</fpage>
<lpage>3332</lpage>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM</article-title>
<source>arXiv</source>
<year>2013</year>
<elocation-id>13033997</elocation-id>
<comment>[q-bio]</comment>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Handsaker</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wysoker</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fennell</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Homer</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Marth</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Abecasis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Durbin</surname>
<given-names>R</given-names>
</name>
</person-group>
<collab>1000 Genome Project Data Processing Subgroup</collab>
<article-title>The Sequence Alignment/Map format and SAMtools</article-title>
<source>Bioinformatics</source>
<year>2009</year>
<volume>25</volume>
<fpage>2078</fpage>
<lpage>2079</lpage>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grubaugh</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Gangavarapu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Quick</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Matteson</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>De Jesus</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Main</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Brackney</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Grewal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gurfield</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>
<article-title>An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar</article-title>
<source>Genome Biology</source>
<year>2019</year>
<volume>20</volume>
<fpage>8</fpage>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nchioua</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kmiec</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Conzelmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Groß</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Neil</surname>
<given-names>SJD</given-names>
</name>
<name>
<surname>Stenger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sauter</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Münch</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Sparrer</surname>
<given-names>KMJ</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite Preadaptation to the Low-CpG Environment in Humans</article-title>
<source>mBio</source>
<year>2020</year>
<volume>11</volume>
<fpage>16</fpage>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Groß</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Conzelmann</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Stenger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Steinhart</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kirchhoff</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Münch</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Detection of SARS-CoV-2 in human breastmilk</article-title>
<source>The Lancet</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1016/S0140-6736(20)31181-8</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<boxed-text id="BX1" position="float" orientation="portrait">
<caption>
<title>Importance</title>
</caption>
<p>Recent results showed that an early SARS-CoV-2 isolate requires endogenously expressed IFITM proteins for efficient infection. However, whether IFITMs are also important cofactors for infection of emerging SARS-CoV-2 VOCs that out-competed the original strains and currently dominate the pandemic remained to be determined. Here, we demonstrate that depletion of endogenous IFITM2 expression almost entirely prevents the production of infectious Alpha, Beta, Gamma and Delta VOC SARS-CoV-2 virions in a human lung cell line. In comparison, silencing of IFITM1 had little impact, while knock-down of IFITM3 had intermediate effects on viral replication. Finally, an antibody targeting the N-terminus of IFITM2 inhibited SARS-CoV-2 VOC replication in iPSC-derived alveolar epithelial type II cells. Our results show that SARS-CoV-2 VOCs including the currently dominant Delta variant are dependent on IFITM2 for efficient replication suggesting that IFITM proteins play a key role in viral transmission and pathogenicity.</p>
</boxed-text>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>Amino acid variations in the Spike proteins of SARS-CoV-2 variants investigated.</title>
<p>The upper panel shows a schematic representation of the SARS-CoV-2 S protein with specific domains indicated in different colours. Abbreviations: SS, signal sequence; NTD, N-terminal domain; RBD, receptor binding domain; FP, fusion peptide; HR, heptad repeat and TMD, transmembrane domain. The S1/S2 and S2’ proteolytic cleavage sites are also indicated.</p>
</caption>
<graphic xlink:href="EMS139954-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>Role of IFITMs in replication of SARS-CoV-2 VOCs in Calu-3 cells.</title>
<p>(<bold>A</bold>) Standard curve and raw qRT-PCR CT values obtained using supernatants of Calu-3 cells collected 2 days post-infection. (<bold>B</bold>) Viral N RNA levels in the supernatant of Calu-3 cells infected with the indicates SARS-CoV-2 variants. Cells were transfected with control (CTRL) or IFITM targeting siRNAs as indicated. Numbers above the bars indicate n-fold reduction compared to the viral RNA levels detected in the supernatant of Calu-3 cells treated with CTRL siRNA. Bars in panel A and B represent the mean of 3 to 4 independent experiments (±SEM) each measured in technical duplicates.</p>
</caption>
<graphic xlink:href="EMS139954-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>Silencing of endogenous IFITM2 expression prevents production of infectious SARS-CoV-2.</title>
<p>(<bold>A</bold>) Supernatants derived from Calu-3 cells treated with control (CTRL) or IFITM2 siRNA two days after infection with the SARS-CoV-2 NL-02-2020 or the indicated VOCs were serially diluted and added to Caco-2 cells seeded in 96-well plates. Five days later, cells were examined for CPE, fixed and stained with crystal violet. Productively infected wells appear transparent since the cells are eliminated or detached due to viral infection. (<bold>B</bold>) Quantification of infectious SARS-CoV-2 particles in the supernatant of Calu-3 cells treated with control or IFITM2 targeting siRNAs. Bars represent the mean of one experiment performed with eight technical replicates (±SD) shown in panel A. Bdl, below detection limit.</p>
</caption>
<graphic xlink:href="EMS139954-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<title>Expression of ACE2 and IFITM proteins in Calu-3 and iATII cells.</title>
<p>(<bold>A</bold>) Immunoblot of ACE2, IFITM1, IFITM2, and IFITM3 in Calu-3 and iATII cells left uninfected (c) or infected with the indicated SARS-CoV-2 variants. Whole-cell lysates were stained with the indicated antibodies. An unspecific signal was observed in the Calu-3 control lane stained with the CoV-2 N antibody. (<bold>B</bold>) Flow cytometric analysis of surface ACE2 expression in Calu-3 and iATII cells.</p>
</caption>
<graphic xlink:href="EMS139954-f004"/>
</fig>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<title>Effect of an α-IFITM2 antibody on replication of SARS-CoV-2 variants in iATII cells.</title>
<p>(<bold>A</bold>) Quantification of viral N RNA levels in the supernatant of iATII cells treated with α-IFITM2 antibody (20, 40, or 80 μg/ml) or Remdesivir (10 μM) 1 h before infection (SARS-CoV-2, MOI 0.5), collected 48 h post-infection. Bars represent the mean of three independent experiments. (<bold>B</bold>) Average percentage of reduction of vRNA levels in the supernatants of (E) compared to the untreated control.</p>
</caption>
<graphic xlink:href="EMS139954-f005"/>
</fig>
</floats-group>
</article>
